BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.63 per share for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2017-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2015-03-31 was $3.07, a 40.73% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2014-03-31 was $5.18, a 362.50% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2013-03-31 was $1.12.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2016 was $2.63, a 39.68% decline from fiscal 2015.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2015 was $4.36, a 8.79% decline from fiscal 2014.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2014 was $4.78, a 101.69% increase from fiscal 2013.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2013 was $2.37, a 50.00% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2016-12-31 | $2.63 10-K · filed 2017-02-27 | |||
| 2015-12-31 | $4.36 10-K · filed 2017-02-27 | |||
| 2015-09-30 | $4.36 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $4.26 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | $3.07 10-Q · filed 2015-05-08 | |||
| 2014-12-31 | $4.78 10-K · filed 2017-02-27 | |||
| 2014-09-30 | $4.86 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $4.90 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | $5.18 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $2.37 10-K · filed 2016-02-26 | |||
| 2013-09-30 | $2.37 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | $1.17 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $1.12 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | $1.58 10-K · filed 2015-03-02 | |||
| 2012-09-30 | $1.61 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | $1.66 10-Q · filed 2012-08-08 | |||
| 2011-12-31 | $1.57 10-K · filed 2014-03-10 | |||
| 2010-12-31 | $2.30 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |